2022
DOI: 10.1186/s13063-022-06977-4
|View full text |Cite
|
Sign up to set email alerts
|

Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights

Abstract: Background The real impact of the degree of association (DoA) between endpoint components of a composite endpoint (CE) on sample size requirement (SSR) has not been explored. We estimate the impact of the DoA between death and acute myocardial infarction (AMI) on SSR of trials using use the CE of major adverse cardiac events (MACE). Methods A systematic review and quantitative synthesis of trials that include MACE as the primary outcome through sea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 36 publications
0
1
0
Order By: Relevance
“…We grouped PT according to the characteristics of adverse events (Supplementary Table 1). Using the International Classi cation of Diseases, clinical revision, the tenth edition (ICD-10-CM) diagnostic code de nes MACE, including cardiovascular death, non-fatal heart attack, non-fatal stroke, heart failure, malignant arrhythmia, myocarditis, pericardial disorders [33][34][35][36]. Other cardiovascular events mainly include general heart disease, bleeding, and thrombosis.…”
Section: De Nition Of Adverse Event Of Interestmentioning
confidence: 99%
“…We grouped PT according to the characteristics of adverse events (Supplementary Table 1). Using the International Classi cation of Diseases, clinical revision, the tenth edition (ICD-10-CM) diagnostic code de nes MACE, including cardiovascular death, non-fatal heart attack, non-fatal stroke, heart failure, malignant arrhythmia, myocarditis, pericardial disorders [33][34][35][36]. Other cardiovascular events mainly include general heart disease, bleeding, and thrombosis.…”
Section: De Nition Of Adverse Event Of Interestmentioning
confidence: 99%